About Alesta Therapeutics
Alesta Therapeutics is a company based in Leiden (Netherlands) founded in 2021. Alesta Therapeutics has raised $67.49 million across 1 funding round from investors including SSI Strategy, RTW Investments and Frazier Life Sciences. Alesta Therapeutics offers products and services including ALE1 and ALE2. Alesta Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Leiden, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$67.49 M (USD)
in 1 rounds
-
Latest Funding Round
$67.49 M (USD), Series A
Jan 08, 2025
-
Investors
SSI Strategy
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alesta Therapeutics
Alesta Therapeutics offers a comprehensive portfolio of products and services, including ALE1 and ALE2.
Oral small molecule for treating hypophosphatasia and related symptoms.
Oral small molecule targeting Charcot-Marie-Tooth disease neurological effects.
Funding Insights of Alesta Therapeutics
Alesta Therapeutics has successfully raised a total of $67.49M through 1 strategic funding round. The most recent funding activity was a Series A round of $67.49 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alesta Therapeutics
Alesta Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include SSI Strategy, RTW Investments and Frazier Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investment firm focused on novel therapeutics development.
|
Locked | Locked | Locked | |
|
Droia Ventures is focused on investing in drug development companies.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Alesta Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alesta Therapeutics
Investment portfolio details for Alesta Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Alesta Therapeutics
Detailed financials for Alesta Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alesta Therapeutics Comparisons
Peer comparison for Alesta Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alesta Therapeutics
Alesta Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of Alesta Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alesta Therapeutics
Complete news archive for Alesta Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alesta Therapeutics
Alesta Therapeutics was founded in 2021 and raised its 1st funding round 4 years after it was founded.
Alesta Therapeutics is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Ilan Ganot is the current CEO of Alesta Therapeutics.
Alesta Therapeutics is a funded company, having raised a total of $67.49M across 1 funding round to date.
Alesta Therapeutics was founded in 2021 and is located in Leiden, Netherlands. Small molecule therapies are developed by the company within the biotechnology sector, targeting chronic stress response pathways for rare diseases. Focus is placed on treatments for Hypophosphatasia, which affects bone fragility and tooth loss in adults, and Charcot-Marie-Tooth, an inherited neurological disorder causing muscle weakness and sensory loss. Operations center on advancing these therapeutics through research and development.
Alesta Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Alesta Therapeutics offers ALE1 and ALE2.
Alesta Therapeutics has 7 investors. Key investors include SSI Strategy, RTW Investments, Frazier Life Sciences, Droia Ventures, and Novartis Venture Fund.